zurück
Remdesivir (new indication: COVID-19, patients not requiring supplemental oxygen, with increased risk of progressing to severe COVID-19)
Subject:
- Active Substance: Remdesivir
- Name: Veklury®
- Therapeutic area: Coronavirus disease 2019 (COVID-19)
- Pharmaceutical company: Gilead Sciences GmbH
Time table:
- Start: 15.01.2022
- Final decision by G-BA: 07.07.2022
Final decision:
- Hint for a minor additional benefit